65,437 trials
Pulmonary Embolism · Venous Thromboembolism · Atrial Fibrillation
Primary: The Number (Proportion) of Notifications (in the Existing-prescription Notification Conditions) That Are Addressed Within 7 Days. — 24.86; 21.74 percent of notifications
Peripheral Nerve Injuries · Neuroma of Nerve Repair · Nerve Graft; Complications, Mechanical
Primary: Motor Functional Recovery (MRC Grade ≥ M3) — 34 Participants
Osteo Arthritis Knee
Primary: Repeat Allogeneic Intra-articular Injection Within 6 Months. — 6; 7 Participants
Physical Inactivity · Cardiovascular Diseases
Primary: Scheduled Minutes of Physical Education/Week — -4.0; 2.3 scheduled minutes of PE per week
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) — 470.3; 295.7; 293.2 titer — p=<0.001
Lung Cancer · Lung Neoplasms/Diagnosis
Primary: Study 1 Primary Outcome: Count of Patients Newly Identified as Eligible for Lung Cancer Screening — 308; 635 Participants
Cellulitis · Cellulitis of Leg · Antibiotic Duration
Primary: Sustained Recovery — 156 Participants
Substance-Related Disorders
Primary: Alcohol and/or Cannabis Use — 8; 2; 7; 2 Participants — p=0.24
Brenner Tumor · Malignant Ascites · Malignant Pleural Effusion
Primary: Progression Free Survival (PFS) — 15.4; 14.3 Months — p=0.31
Drug Use · Opioid-use Disorder
Primary: Illicit Opioid Use — 0.434; 0.360 Proportion of UDS samples
Long COVID-19 · Long COVID
Primary: Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS)…
Out-Of-Hospital Cardiac Arrest · Healthy
Primary: Severe Hypoglycemia — 0; 0; 0; 0 Participants
Anxiety
Primary: Change From Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI) — 20.97; 22.50; 21.00; 6.88 Score — p=<0.001
Early Mobility · Older Adults · Hospital Acquired Condition
Primary: Aim 1: Change in Gait Speed — 0.67; 0.73; 0.73; 0.77 m/s — p=0.674
COVID-19 · Corona Virus Infection
Primary: Participants Who Had a Reaction to an Initial or Additional Dose of the Pfizer-BioNTech or Moderna COVID-19 mRNA Vaccine, or Who Had Long COVID — 71; 2; 1; 1 Participants